Brookstone Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $616K | Sell |
12,855
-6,625
| -34% | -$285K | 0.01% | 869 |
|
|
2026
Q1 | $716K | Buy |
19,480
+3,925
| +25% | +$186K | 0.01% | 751 |
|
|
2025
Q4 | $791K | Sell |
15,555
-8,298
| -35% | -$424K | 0.01% | 703 |
|
|
2025
Q3 | $1.32M | Buy |
23,853
+1,816
| +8% | +$106K | 0.02% | 536 |
|
|
2025
Q2 | $1.52M | Buy |
22,037
+7,848
| +55% | +$534K | 0.02% | 472 |
|
|
2025
Q1 | $985K | Sell |
14,189
-596
| -4% | -$49.2K | 0.01% | 561 |
|
|
2024
Q4 | $1.27M | Sell |
14,785
-1,623
| -10% | -$176K | 0.02% | 463 |
|
|
2024
Q3 | $1.95M | Sell |
16,408
-186
| -1% | -$24.8K | 0.03% | 381 |
|
|
2024
Q2 | $2.25M | Buy |
16,594
+553
| +3% | +$73.3K | 0.04% | 353 |
|
|
2024
Q1 | $2.06M | Sell |
16,041
-10,452
| -39% | -$1.24M | 0.04% | 349 |
|
|
2023
Q4 | $2.74M | Buy |
26,493
+12,154
| +85% | +$1.2M | 0.05% | 283 |
|
|
2023
Q3 | $1.4M | Sell |
14,339
-647
| -4% | -$57K | 0.03% | 373 |
|
|
2023
Q2 | $1.18M | Sell |
14,986
-508
| -3% | -$41.5K | 0.02% | 403 |
|
|
2023
Q1 | $1.33M | Sell |
15,494
-1,114
| -7% | -$79K | 0.03% | 396 |
|
|
2022
Q4 | $1.15M | Buy |
16,608
+958
| +6% | +$56.2K | 0.02% | 405 |
|
|
2022
Q3 | $814K | Sell |
15,650
-15,976
| -51% | -$856K | 0.02% | 441 |
|
|
2022
Q2 | $1.72M | Buy |
31,626
+17,104
| +118% | +$949K | 0.04% | 312 |
|
|
2022
Q1 | $878K | Sell |
14,522
-552
| -4% | -$28.3K | 0.02% | 441 |
|
|
2021
Q4 | $765K | Sell |
15,074
-578
| -4% | -$31.3K | 0.01% | 434 |
|
|
2021
Q3 | $787K | Sell |
15,652
-322
| -2% | -$15.6K | 0.01% | 424 |
|
|
2021
Q2 | $692K | Sell |
15,974
-228
| -1% | -$8.84K | 0.01% | 428 |
|
|
2021
Q1 | $546K | Buy |
16,202
+388
| +2% | +$13.8K | 0.02% | 343 |
|
|
2020
Q4 | $552K | Buy |
15,814
+308
| +2% | +$10.6K | 0.02% | 312 |
|
|
2020
Q3 | $538K | Sell |
15,506
-532
| -3% | -$17.7K | 0.02% | 264 |
|
|
2020
Q2 | $525K | Sell |
16,038
-6,324
| -28% | -$202K | 0.03% | 228 |
|
|
2020
Q1 | $673K | Sell |
22,362
-594
| -3% | -$17.7K | 0.04% | 185 |
|
|
2019
Q4 | $664K | Sell |
22,956
-74
| -0.3% | -$2.05K | 0.03% | 243 |
|
|
2019
Q3 | $595K | Buy |
23,030
+1,348
| +6% | +$34.1K | 0.03% | 242 |
|
|
2019
Q2 | $553K | Buy |
21,682
+4,708
| +28% | +$116K | 0.03% | 242 |
|
|
2019
Q1 | $444K | Buy |
16,974
+2,532
| +18% | +$62.2K | 0.03% | 269 |
|
|
2018
Q4 | $333K | Buy |
14,442
+1,070
| +8% | +$23.8K | 0.03% | 209 |
|
|
2018
Q3 | $315K | Buy |
+13,372
| New | +$326K | 0.02% | 329 |
|
|
2015
Q2 | – | Sell |
-10,918
| Closed | -$291K | – | 2173 |
|
|
2015
Q1 | $291K | Buy |
+10,918
| New | +$251K | 0.04% | 148 |
|
Other funds holding NVO
F
Brookstone Capital Management's NVO Position: Q2 2026 in Review
Brookstone Capital Management reduced its Novo Nordisk (NVO) stake by 34% in Q2 2026, selling an estimated $285K and leaving 12,855 shares worth $616K. The position accounts for 0.01% of the portfolio, ranked #869.
Brookstone Capital Management first reported a position in NVO in Q1 2015 and has held it in 33 quarters since. The position peaked at $2.74M in Q4 2023. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Brookstone Capital Management held 12,855 shares of Novo Nordisk worth $616K as of Q2 2026.
- Brookstone Capital Management sold 6,625 Novo Nordisk shares in Q2 2026, an estimated $285K.
- Novo Nordisk made up 0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #869 holding.
- Brookstone Capital Management first reported a position in Novo Nordisk in Q1 2015 and has held it in 33 quarters since.
- Brookstone Capital Management's Novo Nordisk position peaked at $2.74M in Q4 2023.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.